Improving Healthspan and Increasing Lifespan
Phoenix SENOLYTIX™ is an affiliate of SENOTHERAPEUTIX, Inc.
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others. Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
Phoenix SENOLYTIX is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging. Its lead program, utilizing its proprietary purposeful cell elimination technology, ApoptiCIDe™, targets senescent cells for elimination, restoring the youthful balance of aged or “senescent” and young cells throughout the organs of the body. Our leadership team were the founders of Bellicum Pharmaceuticals, the first CAR-T cell company, in 2004. Inventors of CaspaCIDe™ at Bellicum, the most effective cell therapy safety switch validated in humans, they have now repurposed this technology, previously established as both safe and effective senolytic therapy in the p16Ink4a-ATTAC mouse model of genomic ablation of senescent cells, now as ApoptiCIDe™ to target senescent cells for non-inflammatory, apoptotic elimination, among other uses, in patients. By targeting senescent cells for elimination, we have a unique opportunity to intervene in the aging process in ways that were once thought impossible.
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine, have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc.: (1) Eos SENOLYTIX, a longevity company developing novel gerotherapeutic peptides to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel gerotherapeutic peptides to target cancer via this same novel mechanism as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them!
